ADAP — Adaptimmune Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $73.54m
- -$27.83m
- $178.03m
Annual cashflow statement for Adaptimmune Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -130 | -158 | -165 | -114 | -70.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 12.9 | 27.6 | 19.1 | -11.9 | 23.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 56 | 135 | -1.53 | -25 | -37 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -53.6 | 10.7 | -142 | -141 | -73.2 |
| Capital Expenditures | -2.91 | -8.78 | -29.7 | -4.88 | -2.72 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -276 | 84.6 | 119 | 181 | -56.2 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -279 | 75.8 | 89.1 | 177 | -59 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 340 | 3.29 | 12.9 | 0.88 | 78.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.58 | 90.2 | -42.1 | 37.4 | -53.8 |